Physician profile
Carol Gates
NPI 1215419825
$3,246.46
in general payments reported to CMS, 2019-2025
25 companies · $16.43 in 2025
The $16.43 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,472 · 2022: $1,472 · 2023: $286 · 2025: $16.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $852.14 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $251.05 | 2021-2023 | Trintellix |
| Lilly USA, LLC | $245.03 | 2021-2022 | |
| Novo Nordisk INC | $228.96 | 2022-2023 | Rybelsus, Ozempic, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.67 | 2021-2022 | |
| Pfizer INC. | $214.65 | 2021-2023 | |
| Amarin Pharma, INC. | $129.38 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $121.29 | 2022 | |
| Esperion Therapeutics, INC. | $114.73 | 2021 | |
| Eisai INC. | $114.50 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $112.65 | 2021-2022 | |
| Amgen INC. | $92.35 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $86.02 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.12 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $75.75 | 2021-2023 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $60.43 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $43.97 | 2022 | |
| Boston Scientific Corporation | $37.50 | 2022-2025 | Spaceoar System |
| Glaxosmithkline, LLC. | $31.58 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $30.75 | 2022 | |
| Genentech USA, INC. | $26.57 | 2021 | |
| Lundbeck LLC | $24.06 | 2023 | Rexulti |
| Scynexis, INC. | $22.36 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.75 | 2021 | |
| Currax Pharmaceuticals LLC | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Gates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.